Cipla receives U.S. FDA approval for generic of asthma, COPD drug

This is first dry powder inhaler (DPI) approval from Cipla’s U.S.-based manufacturing network. The product is expected to be launched in the second quarter (Q2) of FY27 in the U.S

· 7/28/2026, 3:36:01 PM· 2 min read

Cipla receives U.S. FDA approval for generic of asthma, COPD drug

This is first dry powder inhaler (DPI) approval from Cipla’s U.S.-based manufacturing network. The product is expected to be launched in the second quarter (Q2) of FY27 in the U.S

Read original story →

Share:Twitter Facebook WhatsApp LinkedIn

Cipla receives U.S. FDA approval for generic of asthma, COPD drug

Related stories

SEBI did not penalise most finfluencers: CFA study

Alembic Pharma gets U.S. FDA nod for generic chronic constipation drug

Some parents on benefits to get up to £4,500 for child starting apprenticeship

City Union Bank Q1 net rises 25% to ₹383 crore